This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Chronic Low Back Pain.

This study has been completed.
Information provided by:
Purdue Pharma LP Identifier:
First received: April 18, 2006
Last updated: May 13, 2013
Last verified: May 2013
The objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (5, 10, and 20 mg) in comparison to placebo transdermal system and immediate release oxycodone/acetaminophen in subjects with chronic low back pain inadequately treated with non-opioid analgesics. The double-blind treatment intervention duration is 60 days.

Condition Intervention Phase
Back Pain Drug: Buprenorphine transdermal delivery system Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Safety and Efficacy of Buprenorphine TDS (Transdermal Delivery System) 5, 10 and 20 Applied Every 7 Days for Sixty Days vs. 5 mg Oxycodone/325 mg Acetaminophen Tablets q6h Prn vs. Placebo in Patients With Chronic Low Back Pain

Resource links provided by NLM:

Further study details as provided by Purdue Pharma LP:

Primary Outcome Measures:
  • Pain on average and pain right now scores at days 0, 9, 15, 30, 45, 60, or if applicable, at early termination.

Secondary Outcome Measures:
  • Brief Pain Inventory
  • dropouts due to lack of efficacy
  • MOS health survey
  • VAS pain intensity
  • therapeutic response
  • patient preference
  • daily patient diary
  • and number of oxycodone/acetaminophen or placebo tablets taken

Estimated Enrollment: 225
Study Start Date: April 1997
Estimated Study Completion Date: January 1998
Detailed Description:
Buprenorphine is a synthetic opioid analgesic with over twenty-five years of international clinical experience indicating it to be safe and effective in a variety of therapeutic situations for the relief of moderate to severe pain. Transdermal systems may offer advantages over currently indicated oral products including ease and convenience of use, improved compliance, possible reduction in patient care, and prolonged and consistent delivery of drug.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • unacceptable pain control despite currently taking a nonsteroidal anti-inflammatory drug considered at a therapeutic and/or tolerated dose or currently taking </=2 short-acting opioid doses per day.
  • taking >/=3 opioid doses per day with or without acceptable pain control.

Exclusion Criteria:

  • receiving opioids at an average daily dose of greater than 60 mg of oral morphine equivalents or subjects receiving more than 6 tablets per day of a short-acting opioid.
  • scheduled to have surgery (including dental) involving the use of post- or preoperative analgesics or anesthetics during the study period.

Other protocol-specific exclusion/inclusion criteria may apply.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00315874

United States, Arizona
Hawthorne & York, Intl, Ltd
Phoenix, Arizona, United States, 85008
Arizona Research & Education
Phoenix, Arizona, United States, 85012
United States, Florida
Gainesville Clinical Research Center
Gainesville, Florida, United States, 32605
Park Place Therapeutic Center
Plantation, Florida, United States, 33324
United States, Georgia
Atlanta Research Center
Atlanta, Georgia, United States, 30033
United States, Indiana
Rheumatology Associates, Inc.
Indianapolis, Indiana, United States, 46260
United States, Michigan
Westside Family Medical Center
Kalamazoo, Michigan, United States, 49009
United States, Missouri
The Center for Pharmaceutical Research
Kansas City, Missouri, United States, 64114
United States, New York
The New York Hospital Cornell Medical Center
New York, New York, United States, 10021
United States, North Carolina
NC Clinical Research, Inc.
Raleigh, North Carolina, United States, 27607
Pain Control Ctr Bowman Gray School of Med
Winston-Salem, North Carolina, United States, 27103
United States, Texas
Metroplex Clinical Research Center
Dallas, Texas, United States, 75235
Sponsors and Collaborators
Purdue Pharma LP
  More Information Identifier: NCT00315874     History of Changes
Other Study ID Numbers: BP96-0102
Study First Received: April 18, 2006
Last Updated: May 13, 2013

Keywords provided by Purdue Pharma LP:
chronic back pain

Additional relevant MeSH terms:
Back Pain
Low Back Pain
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists processed this record on July 21, 2017